What's new in ESMO guidelines?

Professor Emanuela Romano explains what's new in ESMO guidelines on hepatocellular carcinoma, cutaneous melanoma, Hodgkin Lymphomas and early stage and locally advanced non-small cell lung cancers at the ESMO Congress 2025.

T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations

Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups. 

IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.

How to PROC - Breaking the Wall of Platinum-Resistance in Ovarian Cancer

Professor Jalid Sehouli explains how to break the wall of platinum-resistance in ovarian cancer at the ESMO Congress 2025.

Novelties of the treatment of colon cancer at ESMO 2025

Professor Julien Taieb shares his thoughts on the novelties of the treatment of colon cancer at the ESMO Congress 2025.

Immuno-oncology biomarkers in locally advanced HNSCC - lessons from the KeyNote-689 trial

Professor Cécile Badoual shares her thoughts on the immuno-oncology biomarkers in locally advanced HNSCC and explains the lessons from the KeyNote-689 trial after the ESMO Congress 2025.

Unlocking the potential of radioligand therapy for advanced prostate cancer

Professor Irene Burger explains how to unlock the potential of radioligand therapy for advanced prostate cancer at the ESMO Congress 2025.

Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial

Professor Danny Rischin shares his thoughts on the analysis of second primary cutaneous squamous cell carcinoma tumors reported during the C-POST trial were presented at the ESMO Congress 2025. The study is a randomized phase III study of adjuvant cemiplimab vs placebo for high-risk CSCC.

Treatment Landscape in Resectable LA HNSCC

Professor Hisham M. Mehanna shares his thoughts on the treatment landscape in resectable LA HNSCC at ESMO 2005 at the ESMO Congress 2025.

Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial

Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.

KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials

Professor Christof Vulsteke shares her thoughts on the data from the phase 3 KEYNOTE-905 trial were presented at the ESMO Congress 2025. A treatment regimen consisting of neoadjuvant enfortumab vedotin-ejfv plus pembrolizumab, radical cystectomy plus pelvic lymph node dissection, and adjuvant EV plus pembrolizumab yielded significant improvements in multiple outcomes in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.

Overcoming Therapeutic Challenges in High-risk Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Approach

Professor Dirk Schadendorf shares his thoughts on the overcoming therapeutic challenges in high-risk cutaneous squamous cell carcinoma at the ESMO Congress 2025.

DYNAMIC-III trial results: ctDNA blood test is a powerful tool to guide treatment choices for people with advanced colon cancer

Professor Jeanne Tie shares her thoughts on the DYNAMIC-III trial results were presented at the ESMO Congress 2025.